Daisuke Kaya

Thyroid‐stimulating hormone is an independent risk factor of non‐alcoholic fatty liver disease

Kazuki Tahara, Takemi Akahane, Tadashi Namisaki et al. · JGH Open · 2019 · 46 citations · Full text

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients

Kosuke Kaji, Soichiro Saikawa, Hiroaki Takaya et al. · Antibiotics · 2020 · 41 citations · Full text

Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis

Yukihisa Fujinaga, Hideto Kawaratani, Daisuke Kaya et al. · International Journal of Molecular Sciences · 2020 · 35 citations · Full text

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis

Takahiro Ozutsumi, Tadashi Namisaki, Naotaka Shimozato et al. · International Journal of Molecular Sciences · 2020 · 28 citations · Full text

Liver Fibrosis, Immunology, Pathology +25

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats

Daisuke Kaya, Kosuke Kaji, Yuki Tsuji et al. · Cells · 2019 · 26 citations · Full text

Immunology, Cell Death, Tgr5 Activation Modulates +24